AstraZeneca forms Chinese company to boost innovation
AstraZeneca and the Chinese Future Industry Investment Fund (FIIF) have partnered to establish a company focused on discovering, developing and commercialising new medicines.
FIIF is managed by the SDIC Fund Management Company (SDIC Fund), a private equity management company.
Announced yesterday, November 27, the new company will focus on bringing innovative medicines to patients in China faster.
The company, Dizal Pharmaceutical, holds exclusive rights to develop and commercialise three potential medicines currently in pre-clinical development from AstraZeneca’s pipeline in its main therapy areas of oncology, cardiovascular and metabolic diseases, and respiratory.
Dizal Pharmaceutical is also expected to initiate novel clinical programmes. FIIF will contribute funding and expertise in establishing strategic partnerships in China.
Xiaolin Zhang, previously head of AstraZeneca’s Innovation Center China, has been named as CEO of Dizal Pharmaceutical.
Pascal Soriot, CEO of AstraZeneca, explained that by partnering with FIIF, the companies are aiming to “accelerate the local discovery and development of innovative, affordable medicines for patients in China and around the world”.
Guohua Gao, chairman of SDIC Fund, said: “AstraZeneca’s Innovation Center China has an excellent track record of drug discovery, and the synergy created by combining AstraZeneca’s scientific talent and assets with FIIF’s China expertise and funding will help further promote innovation in medical science.”
AstraZeneca’s China headquarters are based in Shanghai and the company has more than 11,000 employees throughout the country.
Did you enjoy reading this story? Sign up to our free newsletters and get stories like this sent straight to your inbox.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk